군유전체학 시장 - 예측(2026-2031년)

The metagenomics market is anticipated to increase at a 8.89% CAGR, from USD 2.916 billion in 2025 to USD 4.86 billion in 2031.

The metagenomics market encompasses the technologies, services, and bioinformatics tools required to analyze the collective genetic material (DNA/RNA) recovered directly from environmental or clinical samples, bypassing the need for isolating and culturing individual organisms. This approach provides an unbiased view of the composition, function, and dynamics of entire microbial communities. The market is propelled by next-generation sequencing (NGS) platforms, specialized library preparation kits, sophisticated computational software for data analysis, and associated laboratory services. It represents a paradigm shift in microbiology, enabling the study of the vast majority of microbes that are unculturable in the lab, thereby unlocking previously inaccessible biological diversity and functional potential.

Market expansion is fundamentally driven by its transformative applications across high-value research and commercial sectors. A primary growth catalyst is the burgeoning role of metagenomics in drug discovery and development. By screening environmental and host-associated microbiomes, researchers can identify novel biosynthetic gene clusters, enzymes, and bioactive compounds with therapeutic potential, offering a powerful route to new antibiotics, anticancer agents, and other pharmaceuticals in an era of rising antimicrobial resistance. Concurrently, metagenomics is revolutionizing clinical diagnostics. Techniques like shotgun metagenomic sequencing enable hypothesis-free pathogen detection, outbreak surveillance, and the characterization of complex microbiome-disease associations, moving beyond single-pathogen tests to comprehensive infectious disease and dysbiosis profiling.

A parallel and powerful driver is the continuous advancement of core enabling technologies. Innovations in NGS, such as increased read lengths, higher throughput, and reduced costs per base, are making large-scale metagenomic surveys more accessible. Equally critical are developments in bioinformatics, including more powerful algorithms for sequence assembly, taxonomic classification, and functional annotation, which are essential for transforming raw sequence data into biological insights. The integration of long-read sequencing technologies is particularly significant, improving the reconstruction of complete microbial genomes from complex mixtures and enhancing the accuracy of analyses.

Geographically, the Asia-Pacific region is emerging as a significant and high-growth market, propelled by substantial governmental and private investments in life sciences research, particularly in drug discovery and precision medicine initiatives. National strategies to build domestic biotechnology capacity are creating a concentrated demand for advanced genomic tools and services, positioning APAC as a key region for market expansion and strategic investment.

Despite its immense potential, the market faces substantial adoption barriers, primarily related to cost and complexity. The total expense of a metagenomics study remains significant, encompassing high-throughput sequencing runs, specialized sample preparation, and substantial computational resources for data storage and analysis. This cost profile can be prohibitive for smaller academic labs, hospitals, or industries outside of well-funded centers. Furthermore, the field requires a rare combination of expertise in molecular biology, microbiology, bioinformatics, and statistics. The scarcity of skilled personnel capable of designing robust studies, processing complex datasets, and interpreting results within a biological context is a major constraint on broader implementation.

The competitive landscape is characterized by large, established life science tools and diagnostics companies that provide integrated platforms (sequencers, consumables, software), alongside specialized bioinformatics firms and service providers offering end-to-end analytical pipelines. Competition centers on the accuracy and depth of taxonomic and functional profiling, the user-friendliness and computational efficiency of analysis software, and the ability to deliver turnkey solutions that lower the technical barrier for end-users. Success hinges on creating scalable, reproducible, and interpretable workflows that deliver actionable biological insights, not just vast datasets.

In conclusion, the metagenomics market is at the forefront of a fundamental expansion in our ability to understand and harness the microbial world. Its growth is structurally supported by critical applications in therapeutic discovery and advanced diagnostics, powered by relentless technological progress. For industry experts, strategic focus must center on democratizing access by driving down costs and simplifying bioinformatic complexity through more automated, cloud-based solutions. Future innovation will likely focus on real-time, portable sequencing applications, the integration of multi-omics data (metatranscriptomics, metabolomics), and the development of standardized databases and analytical frameworks to improve comparability across studies. Success in this market requires providing not just powerful tools, but the integrated ecosystem necessary to translate complex genetic data into validated scientific discoveries and tangible clinical or industrial outcomes.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Metagenomics Market Segmentation

• By Type
• Targeted Sequencing
• Shot-Gun Sequencing
• By Application
• Disease Diagnostics
• Vaccine Development
• Drug Discovery
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. METAGENOMICS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Targeted Sequencing
• 5.3. Shot-Gun Sequencing

6. METAGENOMICS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Disease Diagnostics
• 6.3. Vaccine Development
• 6.4. Drug Discovery
• 6.5. Others

7. METAGENOMICS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. METAGENOMICS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Bio-Rad Laboratories Inc.
• 10.2. Illumina, Inc.
• 10.3. Thermo Fisher Scientific, Inc.
• 10.4. Novogene Co., Ltd.
• 10.5. QIAGEN
• 10.6. Takara Bio, Inc.
• 10.7. Oxford Nanopore Technologies plc
• 10.8. F. Hoffmann-La Roche Ltd.
• 10.9. Eurofins Scientific SE
• 10.10. BGI Group

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations